Matrix metalloproteinase-9 in vascular lesions and endothelial regulation in Kawasaki disease

Circulation Journal

Volumn 74, Issue 8, 2010, Pages 1670-1675

  Sakata, Koichi ^a   Hamaoka, Kenji ^a   Ozawa, Seiichiro ^a   Niboshi, Ayumi ^a   Yahata, Tomoyo ^a   Fujii, Maiko ^a   Hamaoka, Akiko ^a   Toiyama, Kentarou ^a   Nishida, Masashi ^a   Itoi, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Cytokines; Endothelial cells; Kawasaki disease; Matrix metalloproteinase; Polymerase chain reaction

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; FEMALE; FEVER; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASCULAR LESION;

BLOOD VESSELS; CHILD, PRESCHOOL; CORONARY VESSELS; CYTOKINES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FEVER; HUMANS; INFANT; MALE; MATRIX METALLOPROTEINASE 9; MUCOCUTANEOUS LYMPH NODE SYNDROME; UMBILICAL VEINS;

EID: 77955082443     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0980     Document Type: Article

References (36)

1. Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease. I: Pathology and morphogenesis of the vascular changes. Jpn Circ J 1979; 43: 633-643.
2. Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease. II: Distribution and incidence of the vascular lesions. Jpn Circ J 1979; 43: 741-748.
3. Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease: with particular emphases on arterial lesions. Acta Pathol Jpn 1991; 41: 785-797.
4. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-2154.
5. Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992; 7: 120-125.
6. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998; 29: 1020-1030.
7. Leber TM, Talkwill FR. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer 1998; 78: 724-732.
8. Reno F, Bracco P, Costa L, Cannas M. Cytotoxicity and MMP-9 activation induced in human mononuclear cells by UHMWPE oxidation. Biomaterials 2002; 23: 3645-3650.
9. Jacobs SS, Shastry P, Sudhakaran PR. Monocyte-macrophage differentiation in vitro: Modulation by extracellular matrix protein substratum. Mol Cell Biochem 2002; 233: 9 -17.
10. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skwronski J, Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology 2002; 41: 78-87.
11. Nelissen I, Ronsse I, Van Damme J, Opdenakker G. Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta. J Leukoc Biol 2002; 71: 89-98.
12. Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, et al. Elevated serum levels of matrix metallopro-teinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 2001; 125: 340-344.
13. Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 2001; 104: 860-863.
14. Matsuyama T. Tissue inhibitor of metalloproteinases-1 and matrix metalloproteinase-3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis. Pediatr Int 1999; 41: 239-245.
15. Tamarina NA, McMillan WD, Shively VP, Pearce WH. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1997; 122: 264-271.
16. Sakata K, Kita M, Imanishi J, Onouchi Z, Liu Y, Mitsui Y. Effect of Kawasaki disease on migration of human umbilical vein endo-thelial cells. Pediatr Res 1995; 38: 501-505.
17. Vos CM, Gartner S, Ransohoff RM, McArthur JC, Wahl L, Sjulson L, et al. Matrix metalloprotease-9 release from monocytes increases as a function of differentiation: Implications for neuroinfammation and neurodegeneration. J Neuroimmunol 2000; 109: 231-244.
18. Rivera-Marrero CA, Schuyler W, Roser S, Roman J. Induction of MMP-9 mediated gelatinolytic activity in human monocytic cells by cell wall components of M. tuberculosis. Microb Pathog 2000; 29: 231-244.
19. Koide H, Nakamura T, Ebihara I, Tomino Y. Increased mRNA expression of metalloproteinase-9 in peripheral blood monocytes from patients with immunoglobulin A nephropathy. Am J Kidney Dis 1996; 28: 32-39.
20. Seki M, Uzuki M, Ohmoto H, Yoshino K, Maeda S, Kokumun S, et al. Matrix metaloproteinase (MMP-9) in patients with rheumatoid arthritis. Ryumachi 1995; 35: 792-801.
21. Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr, Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purifcation of matrix metalloproteinase 2. Gynecol Oncol 1996; 62: 89-99.
22. Hirao J, Hibi S, Ahdoh T, Ichimura T. High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease. Int Arch Allergy Immunol 1997; 112: 152-156.
23. Lin CY, Lin CC, Hwang B, Chiang BN. Cytokines predict coronary aneurysm formation in Kawasaki disease patients. Eur J Pediatr 1993; 152: 309-312.
24. Cheng YC, Chen LM, Chang MH, Chen WK, Tsai FJ, Tsai CH, et al. Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells. Mol Cell Biochem 2009; 325: 15-23.
25. Pawlak K, Pawlak D, Mysliwiec M. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients: role of oxidative stress. Cytokine 2005; 31: 18-24.
26. Takatsuki S, Ito Y, Takeuchi D, Hoshida H, Nakayama T, Matsuura H, et al. IVIG reduced vascular oxidative stress in patients with Kawasaki disease. Circ J 2009; 73: 1315-1318.
27. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metal-loproteinases regulate neovascularization by acting as pericellular fbrinolysins. Cell 1998; 95: 365-377.
28. Lou J, Gasche Y, Zheng L, Giround C, Morel P, Clements J, et al. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest 1999; 79: 1015-1025.
29. Sugiura H, Hosoda Y. Histopathological and immunohistochemical diagnosis of intractable vasculitis syndromes. Nippon Rinsho 1994; 52: 2034-2040.
30. Amano S, Hazama F, Kubagawa H, Tasaka K, Haebara H, Hamashima Y. General pathology of Kawasaki disease: On the morphological alterations corresponding to the clinical manifestations. Acta Pathol Jpn 1980; 30: 681-694.
31. Benyon RC, Iredale JP. Is liver fibrosis reversible? Gut 2000; 46: 443-446.
32. Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997; 29: 43-54.
33. Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatol-ogy 1996; 24: 176-184.
34. Satoh S, Inou T. Ischemic heart disease 31 years after possible Kawasaki disease. Jpn Circ J 1996; 60: 805-808.
35. Nakamura Y, Aso E, Yashiro M, Uehara R, Watanabe M, Oki I, et al. Mortality among persons with a history of Kawasaki disease in Japan: Mortality among males with cardiac sequelae is significantly higher than that of the general population. Circ J 2008; 72: 134-138.
36. Ricou B, Nicod L, Lacraz S, Welgus HG, Suter PM, Dayer JM. Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154: 346-352.